The panel consisted of primary antibodies against various immune cells, including CD20+ B cells, CD3+ T cells, CD8+ T cells, CD68+ macrophages (Mø), CD163+ tumor-associated macrophages (TAMs), CD14+ monocytes (M), CD15+ neutrophils (NE), FOXP3+ Treg cells, and the proliferation marker Ki67. This evidence concerns the gene CD163 and neoplasm.